The Sprint Fidelis Lead — the Thin Wire That Shocked, Failed, and Stayed Inside

When Medtronic Inc. suspended distribution of the Sprint Fidelis defibrillator lead on 15 October 2007, the gap between what the device promised and what it delivered was already measured in patients shocked awake by a machine guarding a heart that never faltered — and in others whose hearts stopped while a fractured wire stood silent. The Fidelis (models 6930, 6931, 6948, 6949) had been marketed since September 2004 as a refinement of an unglamorous component: the insulated wire that carries the sensing and high-voltage shock between an implantable cardioverter-defibrillator and the heart muscle. Its selling proposition was caliber. At 6.6 French — roughly 2.2 millimeters — it was the thinnest defibrillation lead on the market, slimmer than Medtronic’s own proven Sprint Quattro and easier to thread into the right ventricle. Thinner was sold as better. Thinner was the defect.

The harm took two mirror-image forms. When a Fidelis conductor fractured — and the thin, integrated cables fractured at higher-than-baseline rates near the can and the anchor sleeve — the lead generated electrical noise the ICD misread as a lethal arrhythmia, and the device did what it was built to do: it delivered a 30-to-40-joule shock into a fully conscious patient, sometimes dozens of times in a night. The opposite failure was worse. A fractured conductor could also break the circuit, so that when the patient genuinely arrested, the defibrillator could not deliver the therapy that was its entire reason to exist. Medtronic’s own analysis projected roughly 2.3 percent of leads fracturing within 30 months; independent center series ran far higher, near 3.75 percent per year against 0.6 percent for comparison leads. At least 13 deaths were ultimately linked to the lead.

Medtronic halted sales and recalled all unimplanted Fidelis leads; the FDA designated it Class I, its most serious category, reserved for products that may cause serious injury or death. But the defining feature was what did not happen: the roughly 268,000 leads already inside patients’ chests were largely left there. A defibrillator lead becomes encased in scar and bonded to the heart wall within months, and extraction can tear the vena cava or ventricle and kill the patient on the table. The recall could not undo itself. Patients were handed a probabilistic dilemma — leave a wire with a known, accelerating failure rate, or accept the lethal risk of pulling it — and a management tail that fell heavily on Medicare. A 2010 settlement of roughly 8,100 lawsuits for $268 million closed the litigation; it did not close the chests.

The Guidant Ventak Prizm 2 DR — a Hidden Flaw, a Dead 21-Year-Old, a Guilty Plea

When Guidant Corporation issued its physician advisory on June 17, 2005 and the FDA classified it a Class I recall — the most serious category, reserved for defects with a reasonable probability of serious injury or death — the gap between the device’s promise and its performance had already been measured in a single funeral. The Ventak Prizm 2 DR (Model 1861) was an implantable cardioverter-defibrillator, a machine whose entire purpose is to deliver a life-saving shock at the instant a patient’s heart fibrillates. Guidant had known since February 2002 that a fraction of these units were prone to internal electrical arcing — a short-circuit across degraded insulation that could render the device inert exactly when it was called upon to fire. The company quietly re-engineered the device in November 2002 to fix the flaw, then told the FDA the change did not affect safety or effectiveness, and continued shipping the older, defect-prone inventory it had already built.

The concealed defect became a body on March 14, 2005, when Joshua Oukrop, a 21-year-old college student from Grand Rapids, Minnesota, with hypertrophic cardiomyopathy, collapsed and died on a mountain-biking trip in Utah. His implanted Prizm 2 DR had short-circuited and failed to shock him. His electrophysiologists, Dr. Robert Hauser and Dr. Barry Maron of the Minneapolis Heart Institute, asked Guidant what had happened; the company disclosed that it knew of the failure mode but had no plan to warn physicians. Hauser and Maron took the case to The New York Times, whose reporter Barry Meier published it on May 24, 2005. Public exposure, not the manufacturer’s conscience, forced the recall three days later.

The reckoning was not regulatory but criminal. After a four-year investigation, the U.S. Department of Justice charged Guidant — by then a subsidiary of Boston Scientific, which had acquired it for roughly $27 billion in April 2006 — with making a materially false statement to the FDA about the Prizm 2 DR and failing to report a “correction” to its Contak Renewal defibrillators. Guidant pleaded guilty, and on January 12, 2011 U.S. District Judge Donovan W. Frank in St. Paul ordered it to pay more than $296 million in fines and forfeiture and serve three years of supervised probation — at the time the largest criminal penalty ever imposed for violating the Food, Drug, and Cosmetic Act. The episode became the foundational case for the principle that withholding a known device defect from regulators is not a paperwork lapse but a prosecutable crime.